Myelopeptide-2

Myelopeptide-2 最初分离于猪骨髓细胞培养上清,能够恢复在 HL-60 白血病细胞或麻疹病毒条件抑制下人 T 淋巴细胞的丝裂原反应活性、白细胞介素-2 (IL-2) 合成水平及白细胞介素-2受体 (IL-2R) 表达水平,并参与免疫稳态调节,在抗肿瘤和抗病毒研究中具有广阔的应用前景。
产品编号: MS-D32957 CAS No.: 137833-31-9 分子式: C41H57N7O8 分子量: 775.93
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Myelopeptide-2 最初分离于猪骨髓细胞培养上清,能够恢复在 HL-60 白血病细胞或麻疹病毒条件抑制下人 T 淋巴细胞的丝裂原反应活性、白细胞介素-2 (IL-2) 合成水平及白细胞介素-2受体 (IL-2R) 表达水平,并参与免疫稳态调节,在抗肿瘤和抗病毒研究中具有广阔的应用前景。

生物实验数据

生物活性 Myelopeptide-2, originally isolated from porcine bone marrow cell culture supernatant, can restore mitogen responsiveness, interleukin-2 (IL-2) synthesis levels, and interleukin-2 receptor (IL-2R) expression levels in human T lymphocytes under conditioned suppression by HL-60 leukemia cells or measles virus, and is involved in immune homeostasis regulation, showing broad application prospects in antitumor and antiviral research.
IC50 & Target

IL-2

 

体外研究
(In Vitro)

Myelopeptide-2 (1 ng/mL-0.1 mg/mL; 72 h) restores phytohemagglutinin (PHA, 2.5 mg/mL)-induced proliferation of human peripheral blood T lymphocytes.
Myelopeptide-2 (0.1 mg/mL and 1 mg/mL; 1-3 d) increases the level of the reduced IL-2 synthesis in human T lymphocytes damaged by HL-60 or measles virus.

体内研究
(In Vivo)

Myelopeptide-2 (10 μg/kg; injection; for 20-50 weeks) delays the appearance of urethane-induced tumors and decreases the number of spontaneous and urethane-induced lung tumors in mice with short-term treatment.

Animal Model: Male BALB/c mice (3-month-old) with spontaneous lung tumors
Dosage: 10 μg/kg; accompanied with 0.5 mg/kg Urethane (MS-J76671) or not
Administration: Routine injection; (1) 1 injection of MP-2 and after 7 days 3 injections of MP-2 every other day, (2) or alternating with injections of urethane (4 injections of MP-2; 3 injections of urethane+4 injections of MP-2); (3) 3 injections of MP-2 every other day or (4) alternating with injections of urethane and after 3 weeks 2 injections of MP-2 monthly with one-week interval, a total of 22 injections (25 injections of MP-2; 3 injections of urethane+25 injections of MP-2). For 20-50 weeks.
Result: Significantly lowered the incidence of urethane-induced lung adenomas in animals receiving 4 injections of MP-2 compared to the group receiving urethane alone or in combination with 25 injections of MP-2.

化学信息

分子量 775.93
分子式 C41H57N7O8
CAS No. 137833-31-9
别名 MP-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础